Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Garry Pairaudeau Clear advanced filters

  • Attempts to reduce the number of efficacy- and safety-related failures that may be linked to the physicochemical properties of small-molecule drug candidates have been inconclusive owing to the limited size of data sets from individual companies. Waring and colleagues analyse the largest data set compiled so far on the causes of attrition for oral, small-molecule drug candidates, derived from a pioneering data-sharing effort by AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.

    • Michael J. Waring
    • John Arrowsmith
    • Alex Weir
    Research
    Nature Reviews Drug Discovery
    Volume: 14, P: 475-486

  • The European Lead Factory combines assets and experience from major pharma with innovation and agility of academia and SMEs in a collaborative platform to expand access to high-throughput screening. With many successes heading towards the clinic, the organization is broadening its approach to screening and partnering.

    • Philip S. Jones
    • Sylviane Boucharens
    • Jon S. B. de Vlieger
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 21, P: 245-246

  • Technological advances coupled with novel collaborative strategies for compound sourcing and management are poised to transform the utility of high-throughput screening.

    • Steve Rees
    • Philip Gribbon
    • Garry Pairaudeau
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 15, P: 1-2